You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 25, 2024

Claims for Patent: 8,187,612

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 8,187,612

Title:	Use of the neurotoxic component of a botulinum toxin for treating a spastic muscle
Abstract:	A method and composition for treating a patient suffering from a disease, disorder or condition and associated pain include the administration to the patient of a therapeutically effective amount of a neurotoxin selected from a group consisting of botulinum toxin types A, B, C, D, E, F and G.
Inventor(s):	Aoki; Kei Roger (Coto De Caza, CA), Grayston; Michael W. (Irvine, CA), Carlson; Steven R. (San Mateo, CA), Leon; Judith M. (San Juan Capistrano, CA)
Assignee:	Allergan, Inc. (Irvine, CA)
Application Number:	10/726,904
Patent Claims:	1. A method for treating strabismus, wherein said method is a human medical application and comprises the step of administering to a human patient a therapeutically effective amount of a neurotoxic component of a botulinum toxin type B to thereby treat strabismus wherein the neurotoxic component administered to the human patient has a molecular weight of about 150 kilodaltons, wherein the neurotoxic component is administered by intramuscular injection or by subcutaneous injection, and wherein the administration of the neurotoxic component results in alleviation of the strabismus within 1 day to 7 days. 2. The method of claim 1, wherein between about 0.01 units and about 500 units of the neurotoxic component is administered. 3. The method of claim 1, wherein between about 80 units and about 460 units of the neurotoxic component is administered. 4. A method for treating strabismus, the method comprising the step of administering to a human patient a therapeutically effective amount of a neurotoxic component of botulinum toxin type B to treat strabismus, wherein the neurotoxic component is administered by intramuscular injection or by subcutaneous injection, and the administration of the neurotoxic component results in alleviation of the strabismus within 1 day to 7 days. 5. The method of claim 4, wherein between about 0.01 units and about 500 units of the neurotoxic component is administered. 6. The method of claim 4, wherein between about 80 units and about 460 units of the neurotoxic component is administered.

Details for Patent 8,187,612

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Solstice Neurosciences, Llc	MYOBLOC	rimabotulinumtoxinb	Injection	103846	12/08/2000	⤷ Try a Trial	2013-12-28
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.